Compare FDMT & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDMT | LWLG |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 625.9M |
| IPO Year | 2019 | 2011 |
| Metric | FDMT | LWLG |
|---|---|---|
| Price | $10.21 | $2.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $28.09 | $7.00 |
| AVG Volume (30 Days) | 855.5K | ★ 3.9M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | 15.79 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | $236,855.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.79 | $257.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 230194.60 | 147.74 |
| 52 Week Low | $6.96 | $2.73 |
| 52 Week High | $16.93 | $18.71 |
| Indicator | FDMT | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 31.35 |
| Support Level | $8.43 | N/A |
| Resistance Level | $10.61 | $5.73 |
| Average True Range (ATR) | 0.85 | 0.44 |
| MACD | -0.15 | -0.12 |
| Stochastic Oscillator | 1.07 | 0.21 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.